Trial Profile
A 24-wk randomised, double-blind, multi-centre, active-controlled (pioglitazone) study to evaluate the efficacy, safety & tolerability of tesaglitazar therapy when administered to patients with type 2 diabetes
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Tesaglitazar (Primary) ; Pioglitazone
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms GALLANT-6
- Sponsors AstraZeneca
- 09 Aug 2006 Status change
- 11 Dec 2005 New trial record.